XORTX Therapeutics Inc V.XRTX

Alternate Symbol(s): XRTX

Healthcare

XORTX Therapeutics Inc. is a Canada-based late-stage clinical pharmaceutical company. The Company develops therapies to treat progressive kidney disease modulated by aberrant purine and uric acid metabolism in orphan disease indications, such as autosomal dominant polycystic kidney disease (ADPKD), as well as type 2 diabetic nephropathy (T2DN) and fatty liver disease. It is working to advance its clinical development stage products that target aberrant purine metabolism and xanthine oxidase to decrease or inhibit production of uric acid. The Company has three product development programs: XRx-008, which is a program for the treatment of ADPKD; XRx-101, which is a program to treat acute kidney injury (AKI) associated with respiratory virus infection, AKI and associated health consequences, and XRx- 225, a program for the treatment of T2DN. The Company's XRx-008 program is designed for longer term stable chronic oral dosing of xanthine oxidase inhibitors.

TSXV:XRTX - Post by User

XORTX Therapeutics Inc > Significantly Undervalued and Strong Buy

<< Previous

Bullboard Posts

Next >>

Comment by Richmondon Nov 12, 2021 7:23am

98 Views

Post# 34118443

RE:RE:Significantly Undervalued and Strong Buy

Don't need ANAL-LIST... Just look at the falling share price graph since the ROLLBACK 11.74 to $9.00. Is the share price anywhere close to $9.00????....Nooooooooo!!!!. Lost two third and still spiralling down. You don't need Analyst's Coverage or Rocket Scientist to figure it out for you, Dummyyyy!!!!

KOkidneydisease wrote: Hey Ankle, you mention 'every analyst'. can you share with us who these other analysts are? it would be helpful to investors on this board and those we may share it with.

Thanks

<< Previous

Bullboard Posts

Next >>

Changing Europe’s dependency on HREE from China